Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Pancreatic Neoplasms 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Drug Therapy 3Radiotherapy 2uridine triacetate 1camrelizumab 1bismuth tripotassium dicitrate 1Telbivudine 1Tegafur 1Surgical Procedures, Operative 1Pharmaceutical Services 1Ofloxacin 1Octreotide 1Metronidazole 1Levofloxacin 1Hyperthermic Intraperitoneal Chemotherapy 1Gemcitabine 1Fluorouracil 1Fecal Microbiota Transplantation 1Esomeprazole 1Docetaxel 1Dihydrouracil Dehydrogenase (NADP) 1Clarithromycin 1Cisplatin 1Celecoxib 1Capecitabine 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × uridine triacetate × Gastrointestinal × Clear all
NCT00024427 2012-06-28

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Wellstat Therapeutics

Phase 3 Completed
250 enrolled
Gastrointestinal

Pancreatic Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡